Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XDH | P47989 | 3/20 | 0.63 |
| ▸ | GABBR2 | O75899 | 1/20 | 0.57 |
| ▸ | GABBR1 | Q9UBS5 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | CDK4 | P11802 | 2/20 | 0.50 |
| ▸ | CCND1 | P24385 | 2/20 | 0.50 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.50 |
| ▸ | CDK1 | P06493 | 1/20 | 0.50 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.50 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.50 |
| ▸ | MMP2 | P08253 | 1/20 | 0.49 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14281153 | 0.86 | XDH (0.53) | XDHGABBR2GABBR1ALDH1A1KDM4E | |
| SCHEMBL13176649 | 0.82 | XDH (0.68) | XDHGABBR2GABBR1ALDH1A1KDM4E | |
| SCHEMBL151754 | 0.82 | XDH (0.68) | XDHGABBR2GABBR1ALDH1A1KDM4E | |
| SCHEMBL8848018 | 0.81 | GABBR2 (0.57) | XDHGABBR2GABBR1ALDH1A1KDM4E | |
| SCHEMBL8848024 | 0.81 | GABBR2 (0.57) | XDHGABBR2GABBR1ALDH1A1KDM4E | |
| SCHEMBL7243507 | 0.80 | XDH (0.70) | XDHALDH1A1KDM4EMAPTMAPK1 | |
| SCHEMBL14492368 | 0.80 | XDH (0.70) | XDHALDH1A1KDM4EMAPTMAPK1 | |
| SCHEMBL4608754 | 0.79 | PTGS2 (0.54) | ALDH1A1KDM4EMAPTMMP2ALOX5 | |
| SCHEMBL4608757 | 0.79 | PTGS2 (0.54) | ALDH1A1KDM4EMAPTMMP2ALOX5 | |
| SCHEMBL9163894 | 0.78 | CCNB2 (0.63) | XDHGABBR2GABBR1ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7026518-B2 | Resveratrol analogs | LAILA IMPEX (IN) | 2006-04-11 | — | — | US | claimed |
| US-20040209951-A1 | Novel resveratrol analogs | LAILA IMPEX (IN) | 2004-10-21 | — | — | US | claimed |
| WO-2004000302-A1 | NOVEL RESVERATROL ANALOGS | GOKARAJU GANGA RAJU (IN) | 2003-12-31 | — | — | WO | claimed |
| WO-2020032752-A1 | CATECHIN COMPOUND AND USE THEREOF | 주식회사 엘큐바이오 | 2020-02-13 | — | — | WO | disclosed |
| WO-2020032744-A1 | CATECHIN COMPOUND AND USE THEREOF | 주식회사 엘큐바이오 | 2020-02-13 | — | — | WO | disclosed |
| EP-3102557-B1 | IMPROVED COMPOSITIONS AND METHODS COMPRISING RESVERATROL | BIOCOGENT LLC (US) | 2020-01-29 | — | — | EP | disclosed |
| WO-2011085454-A1 | GP120 -BINDING BENZENE COMPOUNDS AND SACCHARIDE COMPOUNDS | KATHOLIEKE UNIVERSITEIT LEUVEN K.U.LEUVEN R&D (BE) | 2011-07-21 | — | — | WO | disclosed |
| US-7026518-B2 | Resveratrol analogs | LAILA IMPEX (IN) | 2006-04-11 | — | — | US | disclosed |
| US-20040209951-A1 | Novel resveratrol analogs | LAILA IMPEX (IN) | 2004-10-21 | — | — | US | disclosed |
| US-20040209951-A1 | Novel resveratrol analogs | LAILA IMPEX (IN) | 2004-10-21 | — | — | US | disclosed |
| WO-2004000302-A1 | NOVEL RESVERATROL ANALOGS | GOKARAJU GANGA RAJU (IN) | 2003-12-31 | — | — | WO | disclosed |
| WO-2004000302-A1 | NOVEL RESVERATROL ANALOGS | GOKARAJU GANGA RAJU (IN) | 2003-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040209951-A1 | Novel resveratrol analogs | HRH1, CBR1, CBR3 | XDH 2209/4885GABBR2 2028/4885GABBR1 2338/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.